Filing summary
On September 28, 2026, Oncolytics Biotech Inc. filed an 8-K reporting an event under Item 8.01. The company announced updates and progress relating to its REO 033 colorectal cancer study. The supplied filing text does not describe the study updates; it refers to the accompanying press release, Exhibit 99.1.
Financial and operating metrics
This 8-K provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics. It does not provide a comparable-period financial analysis or financial guidance.
Outlook, risks, and contingencies
The supplied text contains no specific outlook, management commentary, risk disclosures, or contingencies regarding the study. The Item 8.01 information and Exhibit 99.1 are furnished, not deemed filed for purposes of Exchange Act Section 18.
Key facts to verify
- Review Exhibit 99.1, the September 28, 2026 press release, for the substance of the REO 033 study updates and progress.
- Confirm any study milestones, results, timing, or qualifications in the press release; these details are not present in the supplied filing text.